Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma

2004 ◽  
Vol 111 (5) ◽  
pp. 741-745 ◽  
Author(s):  
Simone Mocellin ◽  
Paolo Del Fiore ◽  
Laura Guarnieri ◽  
Romano Scalerta ◽  
Mirto Foletto ◽  
...  
2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Ettore De Berardinis ◽  
Gian Maria Busetto ◽  
Alessandro Sciarra ◽  
Cristiano Cristini ◽  
Francesco Minisola ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (9) ◽  
pp. e74079 ◽  
Author(s):  
Adriana Lasa ◽  
Arnal Garcia ◽  
Carmen Alonso ◽  
Pilar Millet ◽  
Mónica Cornet ◽  
...  

2011 ◽  
Vol 131 (8) ◽  
pp. 1776-1777 ◽  
Author(s):  
Vincenzo De Giorgi ◽  
Pamela Pinzani ◽  
Francesca Salvianti ◽  
Marta Grazzini ◽  
Claudio Orlando ◽  
...  

2003 ◽  
Vol 21 (18) ◽  
pp. 3469-3478 ◽  
Author(s):  
G. Wiedswang ◽  
E. Borgen ◽  
R. Kåresen ◽  
G. Kvalheim ◽  
J.M. Nesland ◽  
...  

Purpose: This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. Patients and Methods: BM aspirates were collected from 817 patients at primary surgery. Tumor cells in BM were detected by immunocytochemistry using anticytokeratin antibodies (AE1/AE3). Analyses of the primary tumor included histologic grading, vascular invasion, and immunohistochemical detection of c-erbB-2, cathepsin D, p53, and estrogen receptor (ER)/progesterone receptor (PgR) expression. These analyses were compared with clinical outcome. The median follow-up was 49 months. Results: ITC were detected in 13.2% of the patients. The detection rate rose with increasing tumor size (P = .011) and lymph node involvement (P < .001). Systemic relapse and death from breast cancer occurred in 31.7% and 26.9% of the BM-positive patients versus 13.7% and 10.9% of BM-negative patients, respectively (P < .001). Analyzing node-positive and node-negative patients separately, ITC positivity was associated with poor prognosis in the node-positive group and in node-negative patients not receiving adjuvant therapy (T1N0). In multivariate analysis, ITC in BM was an independent prognostic factor together with node, tumor, and ER/PgR status, histologic grade, and vascular invasion. In separate analysis of the T1N0 patients, histologic grade was independently associated with both distant disease-free survival (DDFS) and breast cancer–specific survival (BCSS), ITC detection was associated with BCSS, and vascular invasion was associated with DDFS. Conclusion: ITC in BM is an independent predictor of DDFS and BCSS. An unfavorable prognosis was observed for node-positive patients and for node-negative patients not receiving systemic therapy. A combination of several independent prognostic factors can classify subgroups of patients into excellent and high-risk prognosis groups.


Author(s):  
Brigitte Rack ◽  
Christian Schindlbeck ◽  
Julia Jückstock ◽  
Ulrich Andergassen ◽  
Philip Hepp ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document